ClinicalTrials.gg
Active, not recruitingNCT04349657SUPERSURG-RCTUpdated Oct 13, 2026

A Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy

An interventional study of Supera Peripheral Stent System treatment group and Endarterectomy treatment group in Peripheral Arterial Disease, sponsored by KANDO Research. Active, not recruiting at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by KANDO Research · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 85 studies in Peripheral Arterial Disease with a site in Belgium — 8 open to participants now, 17 under way, 3 of them phase 3. Peripheral Arterial Disease · Belgium.

Planned enrollment
16th of 58
286 · median 120
Started
2020
with 4 others
No phase
34 of 85
2 open now
Primary completion
2027-05
later than 10 of 16 live
Registered
66th of 85
by date
Lead sponsor
3 of 85
KANDO Research

Among the 85 studies in Peripheral Arterial Disease with a site in Belgium, this one is the 16th largest by planned enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2020, is one of 34 with no phase, reaches primary completion later than 10 of the 16 other live ones, and was the 66th registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

8 of the 85 studies in Peripheral Arterial Disease with a site in Belgium are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Peripheral Arterial Disease with a site in Belgium, or all of them as a file.
02

Study summary

The SUPERSURG RCT trial investigates the efficacy and safety of the endovascular treatment of stenosis or restenosis in the common femoral artery (CFA) of patients presenting with Rutherford classification 2,3 or 4 with a Supera Vascular Mimetic Implant of Abbott, compared to classic surgical common femoral artery endarterectomy. The Supera Vascular Mimetic Implant has an interwoven design and has a high crush resistance and is, when correctly implanted, an ideal stent to treat eccentric calcified plaques in the CFA.

An expected total of 143 patients will be treated with the Vascular Mimetic Implant of Abbott and compared to a control group of another 143 patients that will be treated with classic surgical endarterectomy of the common femoral artery. Assignment to the treatment groups will be at random.

Patients will be invited for a follow-up visit at 1, 6, 12, 24 and 36 months post-procedure.

The primary efficacy endpoint is defined as follows: freedom from clinically-driven target lesion revascularization and binary restenosis at 12 months. The primary safety endpoint is defined as follows: a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularisation and wound related complications through 30 days post-index procedure.

The secondary endpoints are defined as technical success, primary patency in the deep femoral artery, primary patency in the target lesion, target lesion revascularisation, target vessel revascularisation, binary restenosis, duration of initial hospital stay, sustained clinical improvement, change of walking impairment questionnaire score from baseline, change in target limb Rutherford classification, change in target limb ABI/TBI from baseline, all cause death, thrombosis at the target lesion through 6, 12, 24 and 36 months post-procedure.

Read the detailed description

The objective of this clinical investigation is to assess the safety and efficacy of the Supera Vascular Mimetic Implant for the treatment of stenotic or restenotic lesions of the common femoral artery. Furthermore, a non-inferiority hypothesis in terms of efficacy and a superiority in terms of safety will be tested with the endovascular treatment with Supera compared to surgical endarterectomy of the common femoral artery.

The patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should be geographically stable, willing and able to cooperate in this clinical study, and remain available for long term follow-up. The patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following will be collected: an informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of acute limb ischemia (Rutherford category), the resting ankle-brachial index (ABI) or toe-brachial index (TBI), blood sample test (complete blood count, comprehensive metabolic panel and if applicable pregnancy test) and a walking impairment questionnaire. Randomization will also occur prior to the procedure.

During the procedure patients that are randomized within the endarterectomy group will be treated according to the institutions standard of care. For patients that are randomized within the Supera arm, the guidewire will cross the entire study lesion after which the lesion will be assessed through angiography. Pre-dilatation of the target lesion with an uncoated PTA-balloon is mandatory and will be followed by stenting with the Supera stent according to the instructions for use. Postdilatation of the stent is allowed but not mandatory.

The regular follow-up is necessary to monitor the condition of the patient and the results of the procedure. The patients will be invited for the following required follow-up visits at 1, 6, 12, 24 and 36 months. During these visit the following data will be collected: medication record, physical exam, target limb ABI/TBI and Rutherford classification, duplex ultrasound of target vessel, walking impairment questionnaire and possible adverse events.

03

Conditions studied

  • Peripheral Arterial Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is ≥18 years old
  • Patient presenting a score from 2 to 4 following Rutherford classification
  • Patient is willing to comply with specified follow-up evaluations at the specified times
  • Patient understands the nature of the procedure and provides written , prior to enrolment in the study
  • Patient has a of at least 12 months
  • Prior to enrolment, the guidewire has crossed the target lesion in the endovascular arm. In the surgical arm, the endarterectomy needs to be performed with primary suture or patch implantation
  • De novo stenotic or restenotic (post-PTA) lesions (\<100%) located in the common femoral artery, suitable for both endovascular therapy and endarterectomy
  • Target lesion is located within the native CFA: localized between 1cm proximal to the origin of the circumflex iliac artery and the proximal (2cm) superficial femoral artery and deep femoral artery (2cm) (Azéma type 2 and 3 lesions)
  • There is angiographic evidence of a patent deep femoral artery and/or superficial femoral artery
  • The target lesion has angiographic evidence of >50% stenosis. Occlusions are not allowed.

Exclusion criteria

Exclusion Criteria:

  • Presence of another stent in the target vessel that was placed during a previous procedure
  • Previous open surgery in the ipsilateral groin
  • Patients for antiplatelet therapy, anticoagulants or thrombolytics
  • Patients who exhibit persistent acute intraluminal thrombus at the target lesion site
  • Patients with known to nickel-titanium and heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
  • Known allergy to contrast media that cannot be adequately pre-medicated prior to study procedure
  • Patients with uncorrected bleeding disorders
  • Female patients with child bearing potential not taking adequate or currently breastfeeding
  • Ipsilateral inflow (aorto-iliac) artery treatment before target lesion treatment with a residual stenosis >30%
  • Use of thrombectomy, atherectomy or laser device during procedure
  • Any patient considered to be hemodynamically unstable at onset of procedure
  • Severe medical comorbidities (untreated coronary artery disease/congestive heart failure, severe , , dementia, etc.) or other medical condition that would prelude compliance with the study protocol or 1-year
  • Major distal amputation (above the ankle) in the study limb or non-study limb
  • Target lesion involves an (pseudo-)aneurysm or is adjacent to an (pseudo-)aneurysm (within 5mm)
  • Iliac inflow disease requiring treatment, unless the iliac artery disease is successfully treated first during the index procedure. Success is defined as ≤30% residual diameter stenosis without death or major complications
  • Presence of an aortic, iliac or femoral artificial graft
  • Occlusion in the target lesion
  • Presence of an interposition graft with/without profunda reimplantation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (estimated)

Study arms

  • Experimental
    Supera Peripheral Stent System treatment group

    These patients will be treated endovascularly with the Supera Peripheral Stent System (Abbott).

    Device: Supera Peripheral Stent System treatment group

  • Active comparator
    Endarterectomy treatment group

    These patients will be treated surgically with endarterectomy

    Procedure: Endarterectomy treatment group

Interventions

  • DeviceSupera Peripheral Stent System treatment group

    Percutaneous endovascular stenting with the Supera Peripheral Stent System

  • ProcedureEndarterectomy treatment group

    Surgical treatment through endarterectomy

06

What researchers measure

Primary outcomes

  1. Primary efficacy endpoint at 12 months: Primary patency

    To demonstrate the non-inferior efficacy in the group treated with the Supera stent compared to the group treated with endarterectomy for the treatment of atherosclerosis in the common femoral artery (CFA). Efficacy is defined as primary patency: freedom from restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by an independent DUS core lab in CFA without a previous target lesion revascularization through 12 months post-index procedure.

    Time frame: 12 months post-index-procedure

  2. Primary safety endpoint at 30 days post-index procedure

    To demonstrate superior safety in the group treated with the Supera stent compared to the endarterectomy group for the treatment of atherosclerosis in the CFA. Safety is defined as a composite of overall death, cardiac, pulmonary, renal complications, sepsis, target lesion revascularization (TLR) and wound-related complications (haematoma, seroma, lymphocele, lymphatic leaks with lymphatic fistula, surgical site infections (SSIs) (Szilagyi grade I, II and III)).

    Time frame: 30 days post-index-procedure

Secondary outcomes

  1. Technical success: post-procedure residual stenosis <30%

    Supera group: Defined as the ability to cross and stent the lesion to achieve residual angiographic stenosis no greater than 30%. Endarterectomy group: defined as the ability to remove the atherosclerotic plaque with or without patch (interposition grafts are not allowed). In the imaging subcohort the endarterectomy is considered successful when a residual stenosis no greater than 30% per visual estimation is confirmed.

    Time frame: Index procedure

  2. Primary patency in the deep femoral artery (DFA), post-index procedure and at 6-, 12-, 24- and 36-months post-index procedure

    Primary patency in the DFA is defined as freedom from an occlusion in the DFA as assessed by PSV-values. This PSV-value will be assessed pre-procedure, post-procedure, 6 months and 12 months post-index procedure. At 12 months, the PSV-value will be core-lab controlled.

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  3. Primary patency at 6, 24 and 36 months

    Primary patency is a composite of freedom from clinically-driven target lesion revascularization (CD-TLR) and binary restenosis (restenosis defined as duplex ultrasound (DUS) peak systolic velocity ratio (PSVR) ≥2.4 or ≥50% stenosis as assessed by DUS in CFA) through 6 months post-index procedure

    Time frame: 6, 24 and 36 months post-index-procedure

  4. TLR at 6-, 12-, 24- and 36-months post-index procedure

    TLR is defined as a reintervention to maintain or restore the patency in the target lesion. TLR is clinically-driven (CD) when the TLR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  5. TVR at 6-, 12-, 24- and 36-months post-index procedure

    Target vessel revascularization (TVR) is defined as a reintervention to maintain or restore the patency in the target vessel. TVR is clinically-driven (CD) when the TVR was needed due to symptoms or drop of ankle brachial index (ABI) of ≥20% or \>0.15 when compared to post-procedure

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  6. Binary restenosis at 6, 12, 24 and 36 months

    Binary restenosis is defined as restenosis confirmed by DUS PSVR ≥2.4 or ≥50% stenosis as assessed by angiographic and DUS images. At 12 months, the images will be core lab controlled

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  7. Duration of initial hospitalisation stay

    Number of hours/days of the initial hospitalisation stay.

    Time frame: Up to 4 weeks

  8. Sustained clinical improvement at 6-, 12-, 24- and 36-months post-index procedure

    Clinical improvement is defined as freedom from major target limb amputation, TVR, worsening target limb Rutherford class (compared to baseline) and decrease in target limb ankle brachial index (ABI) or toe brachial index (TBI) ≥0.15 (compared to baseline)

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  9. Change in Walking Impairment Questionnaire (WIQ) score from baseline to 6, 12, 24 and 36 months

    change in walking impairment questionnaire (WIQ) score from baseline to 6 and 12 months. The WIQ consists of 6 sections each consisting of multiple questions. Each question is scored from 0 to 4 (0 meaning a lot of problems and 4 no problems at all). The scores per section are summed up and recalculated to percentages (100% meaning very good and 0% meaning very bad). All the sections are averaged to give the final WIQ-score.

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  10. Change in target limb Rutherford class from baseline to 6, 12, 24 and 36 months

    Change in target limb Rutherford class from baseline to 6, 12, 24 and 36 months

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  11. Change in target limb resting ABI or TBI from baseline to 6, 12, 24 and 36 months

    Change in target limb resting ABI or TBI from baseline to 6, 12, 24 and 36 months

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  12. All cause death at 6, 12, 24 and 36 months

    All cause death at 6, 12, 24 and 36 months

    Time frame: 6, 12, 24 and 36 months post-index-procedure

  13. Thrombosis at the target lesion at 6, 12, 24 and 36 months

    Thrombosis at the target lesion at 6, 12, 24 and 36 months

    Time frame: 6, 12, 24 and 36 months post-index-procedure

07

Study locations

13 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for May 2027, 84 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 84 months is above that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 16, 2020
StartActual
May 5, 2020
Primary completionEst.
May 2027
CompletionEst.
Sep 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT04349657
Lead sponsor
KANDO Research
Collaborators
Xper Research
Responsible party
Sponsor
First posted
Apr 16, 2020
Start date
May 5, 2020
Primary completion
May 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Koen Deloose, MD
principal investigator · A.Z. Sint-Blasius

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion